New drugs for treatment of multiple myeloma
- 1 July 2004
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 5 (7) , 430-442
- https://doi.org/10.1016/s1470-2045(04)01511-6
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With MyelomaJournal of Clinical Oncology, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003
- Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple MyelomaLeukemia & Lymphoma, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospectsSeminars in Cancer Biology, 2000
- Thalidomide in the Treatment of Relapsed Multiple MyelomaMayo Clinic Proceedings, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996